Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 1/2014

01-01-2014 | Research Article

Overexpression of retinoic acid-induced protein 3 predicts poor prognosis for hepatocellular carcinoma

Authors: J. Zheng, X. Guo, X. Gao, H. Liu, Y. Tu, Y. Zhang

Published in: Clinical and Translational Oncology | Issue 1/2014

Login to get access

Abstract

Aim

To investigate clinical significance of retinoic acid-induced protein 3 (RAI3) in hepatocellular carcinoma (HCC).

Methods

Expression of RAI3 at both mRNA and protein levels in tumor, para-tumor and normal liver tissues was detected in 106 HCC patients by real-time quantitative RT-PCR, Western blot and immunohistochemistry. Then, the correlation of RAI3 expression with clinicopathological characteristics and survivals of HCC patients was analyzed.

Results

Our data first found that RAI3 mRNA and protein expression were both significantly higher in HCC than in para-tumor (both P < 0.001) and normal liver tissues (both P < 0.001). The correlation analysis showed a positive correlation between RAI3 mRNA level and RAI3 protein level in HCC tissues (r = 0.8, P < 0.001). Immunohistochemistry data also revealed that overexpression of RAI3 was present in 73.6 % (78/106) of HCC tissues. In addition, high RAI3 protein expression was correlated with advanced TNM stage (P = 0.001), high serum AFP (P = 0.008), vascular invasion (P = 0.01) and tumor recurrence (P = 0.008). Moreover, HCC patients with overexpression of RAI3 had significantly shorter overall (P = 0.01) and disease-free survival (P = 0.01). Furthermore, multivariate analysis showed that overexpression of RAI3 was an independent prognostic factor for both overall (P = 0.02) and disease-free survival (P = 0.03) in HCC.

Conclusion

Our data for the first time provide a basis for the concept that overexpression of RAI3 may contribute to the malignant progression of HCC and predict poor prognosis for patients with this deadly disease after curative hepatectomy. RAI3 might be an important marker for tumor progression and prognosis, as well as a potential therapeutic target of HCC.
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRef
2.
3.
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.PubMedCrossRef
4.
Jörissen H, Bektas N, Dahl E, Hartmann A, ten Haaf A, Di Fiore S, et al. Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancer. BMC Cancer. 2009;9:200.PubMedCentralPubMedCrossRef
5.
Chen Y, Deng J, Fujimoto J, Kadara H, Men T, Lotan D, et al. Gprc5a deletion enhances the transformed phenotype in normal and malignant lung epithelial cells by eliciting persistent Stat3 signaling induced by autocrine leukemia inhibitory factor. Cancer Res. 2010;70:8917–26.PubMedCentralPubMedCrossRef
6.
Robbins MJ, Michalovich D, Hill J, Calver AR, Medhurst AD, Gloger I, et al. Molecular cloning and characterization of two novel retinoic acid-inducible orphan G-protein-coupled receptors (GPRC5B and GPRC5C). Genomics. 2000;67:8–18.PubMedCrossRef
7.
Tao Q, Cheng Y, Clifford J, Lotan R. Characterization of the murine orphan G-protein-coupled receptor gene Rai3 and its regulation by retinoic acid. Genomics. 2004;83:270–80.PubMedCrossRef
8.
Fujimoto J, Kadara H, Garcia MM, Kabbout M, Behrens C, Liu DD, et al. G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer. J Thorac Oncol. 2012;7:1747–54.PubMedCentralPubMedCrossRef
9.
Nagahata T, Sato T, Tomura A, Onda M, Nishikawa K, Emi M. Identification of RAI3 as a therapeutic target for breast cancer. Endocr Relat Cancer. 2005;12:65–73.PubMedCrossRef
10.
Cheng L, Yang S, Yang Y, Zhang W, Xiao H, Gao H, et al. Global gene expression and functional network analysis of gastric cancer identify extended pathway maps and GPRC5A as a potential biomarker. Cancer Lett. 2012;326:105–13.PubMedCrossRef
11.
Zougman A, Hutchins GG, Cairns DA, Verghese E, Perry SL, Jayne DG, et al. Retinoic acid-induced protein 3: identification and characterisation of a novel prognostic colon cancer biomarker. Eur J Cancer. 2013;49:531–9.PubMedCrossRef
12.
Wang W, Zhao LJ, Yang Y, Wang RY, Ren H, Zhao P, et al. Retinoic acid induced 16 enhances tumorigenesis and serves as a novel tumor marker for hepatocellular carcinoma. Carcinogenesis. 2012;33:2578–85.PubMedCrossRef
13.
Guo XD, Xiong L, Zou L, Zhao JM. Upregulation of bone morphogenetic protein 4 is associated with poor prognosis in patients with hepatocellular carcinoma. Pathol Oncol Res. 2012;18:635–40.PubMedCrossRef
14.
Hirano M, Zang L, Oka T, Ito Y, Shimada Y, Nishimura Y, et al. Novel reciprocal regulation of cAMP signaling and apoptosis by orphan G-protein-coupled receptor GPRC5A gene expression. Biochem Biophys Res Commun. 2006;351:185–91.PubMedCrossRef
15.
Acquafreda T, Soprano KJ, Soprano DR. GPRC5A: a potential tumor suppressor and oncogene. Cancer Biol Ther. 2009;8:963–5.PubMedCrossRef
16.
Connolly R, Nguyen NK, Sukumar S. Molecular Pathways: Current Role and Future Directions of the Retinoic Acid Pathway In Cancer Prevention and Treatment. Clin Cancer Res. 2013 (in press).
17.
Shim E, Yeum KJ, Tang G, Ahn SH, Hwang J, Lee-Kim YC. Retinoids, carotenoids, and tocopherols in breast adipose tissue and serum of benign breast disease and breast cancer patients. Nutr Cancer. 2012;64:956–63.PubMedCrossRef
18.
Garattini E, Paroni G, Terao M. Retinoids and breast cancer: new clues to increase their activity and selectivity. Breast Cancer Res. 2012;14:111.PubMedCrossRef
19.
Kadara H, Fujimoto J, Men T, Ye X, Lotan D, Lee JS, et al. A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomas. Neoplasia. 2010;12:499–505.PubMedCentralPubMed
20.
Deng J, Fujimoto J, Ye XF, Men TY, Van Pelt CS, Chen YL, et al. Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis. Cancer Prev Res (Phila). 2010;3:424–37.PubMedCrossRef
21.
Wu Q, Ding W, Mirza A, Van Arsdale T, Wei I, Bishop WR, et al. Integrative genomics revealed RAI3 is a cell growth-promoting gene and a novel P53 transcriptional target. J Biol Chem. 2005;280:12935–43.PubMedCrossRef
Metadata
Title
Overexpression of retinoic acid-induced protein 3 predicts poor prognosis for hepatocellular carcinoma
Authors
J. Zheng
X. Guo
X. Gao
H. Liu
Y. Tu
Y. Zhang
Publication date
01-01-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 1/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1040-2

Other articles of this Issue 1/2014

Clinical and Translational Oncology 1/2014 Go to the issue

Research Article

Does the extent of lymph nodes dissection affect the prognosis of resected stage IA non-small cell lung cancer?

Acknowledgement to Referees

Acknowledgement to Referees 2013

Brief Research Article

Variants in phospholipid metabolism and upstream regulators and non-small cell lung cancer susceptibility

Special Article

Time trends of cancer incidence and mortality in Catalonia during 1993–2007

Review Article

Objective: tumor. Strategies of drug targeting at the tumor mass level

Research Article

Clinical analysis of prophylactic central neck dissection for papillary thyroid carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits